25,287 results match your criteria Chronic Lymphocytic Leukemia


The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.

Blood Adv 2020 Jul;4(13):3072-3084

Department of Malignant Hematology.

The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic leukemia (CLL). However, a high incidence of adverse events has led to frequent discontinuations, limiting the clinical development of these inhibitors. By contrast, the dual PI3Kδ/casein kinase-1-ε (CK1ε) inhibitor umbralisib (TGR-1202) also shows high rates of response in clinical trials but has an improved safety profile with fewer severe adverse events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2020001800DOI Listing

Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents.

Curr Med Res Opin 2020 Jul 7. Epub 2020 Jul 7.

Parexel International, Parexel Access Consulting, Mohali, Punjab, India.

To quantify the health-related quality of life (HRQoL) and economic burden of chronic lymphocytic leukemia (CLL). Studies were searched through Embase, MEDLINE, PubMed, and Cochrane Library, as well as conference abstracts (1 January 2000-2 June 2019). Overall, 12 and 17 primary studies were included in the HRQoL and economic burden reviews, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2020.1784120DOI Listing

Assessing the impact of excluded attributes on choice in a discrete choice experiment using a follow-up question.

Health Econ 2020 Jul 6. Epub 2020 Jul 6.

Health Preference Assessment, RTI Health Solutions, Belfast, UK.

Health researchers design discrete choice experiments (DCEs) to elicit preferences over attributes that define treatments. A DCE can accommodate a limited number of attributes selected by researchers based on numerous factors (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hec.4124DOI Listing

BCL11A Is Oncogenic and Predicts Poor Outcomes in Natural Killer/T-Cell Lymphoma.

Front Pharmacol 2020 4;11:820. Epub 2020 Jun 4.

Department of Hematological Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

The current treatment for natural killer/T-cell lymphoma (NKTL) among advanced/relapsed patients is unsatisfying, thereby highlighting the need for novel therapeutic targets. B-cell chronic lymphocytic leukemia/lymphoma 11 A (BCL11A), as a transcription factor, is oncogenic in several neoplasms. However, its function in NKTL remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2020.00820DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311857PMC

Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells.

Int J Med Sci 2020 30;17(10):1375-1384. Epub 2020 May 30.

Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Cladribine is a purine nucleoside analog used to treat B-cell chronic lymphocytic leukemia and hairy cell leukemia, also functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. The therapeutic role of cladribine against diffuse large B-cell lymphoma cells (DLBCL) is still undefined. In the present study, we demonstrated that cladribine inhibited cell proliferation and induced G phase arrest in human DLBCL cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijms.41793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330656PMC

[Understanding and therapeutic targeting of aberrant mRNA splicing mechanisms in oncogenesis].

Rinsho Ketsueki 2020 ;61(6):643-650

Department of Hematology-Oncology, Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe.

Splicing factor 3b subunit 1 (SF3B1) is the most commonly mutated RNA splicing factor identified in myelodysplastic syndrome (MDS), chronic lymphocytic leukemia, and uveal melanoma. The mechanisms by which SF3B1 mutations promote malignancy are poorly understood. Here, we integrated pan-cancer RNA sequencing to identify mutant SF3B1-dependent aberrant splicing events with a positive CRISPR screen to prioritize alterations that functionally promote oncogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.61.643DOI Listing
January 2020

Bone marrow coexistence of chronic lymphocytic leukemia and Langerhans cell sarcoma.

Ann Hematol 2020 Jul 3. Epub 2020 Jul 3.

Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, Terni, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04167-3DOI Listing

Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.

Anticancer Res 2020 Jul;40(7):4059-4066

Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.

Background/aim: To study the long-term clinical efficacy and tolerability of ibrutinib monotherapy in real-world relapsed and refractory chronic lymphocytic leukemia (RR-CLL) patients outside clinical trials.

Patients And Methods: Clinical data of 171 RR-CLL patients treated with ibrutinib were collected within the observational study of the Polish Adult Leukemia Study Group.

Results: Median patient age was 64 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14403DOI Listing

Leukostasis in Chronic Lymphocytic Leukemia.

Am J Case Rep 2020 Jul 3;21:e924798. Epub 2020 Jul 3.

Department of Medicine, Division of Hematology and Oncology, State University New York (SUNY) Downstate Medical Center, Brooklyn, NY, USA.

BACKGROUND Chronic lymphocytic leukemia (CLL) is a mature B cell lymphocytic neoplasm that has an indolent clinical course. Therefore, not all patients with CLL require treatment at the time of diagnosis. Hyperleukocytosis (white blood cell count, >100×10⁹/L) is present in a large proportion of patients with CLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.924798DOI Listing

Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Haematologica 2020 Jul 2. Epub 2020 Jul 2.

Hematopathology Section, Hospital Cllinic, University of Barcelona, Barcelona, Spain

Chronic lymphocytic leukemia is a well-defined lymphoid neoplasm with very heterogeneous biological and clinical behavior. The last decade has been remarkably fruitful in novel findings elucidating multiple aspects of the pathogenesis of the disease including mechanisms of genetic susceptibility, insights into the relevance of immunogenetic factors driving the disease, profiling of genomic alterations, epigenetic subtypes, global epigenomic tumor cell reprogramming, modulation of tumor cell and microenvironment interactions, and dynamics of clonal evolution from early steps in monoclonal B cell lymphocytosis to progression and transformation into diffuse large B-cell lymphoma. All this knowledge has offered new perspectives that are being exploited therapeutically with novel target agents and management strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.236000DOI Listing

T cell dynamics in chronic lymphocytic leukemia under different treatment modalities.

Clin Cancer Res 2020 Jul 2. Epub 2020 Jul 2.

Centre for Research and Technology Hellas, Institute of Applied Biosciences

Background: Using next-generation sequencing (NGS), we recently documented T cell oligoclonality in treatment-naive chronic lymphocytic leukemia (CLL), with evidence indicating T cell selection by restricted antigens.

Experimental Design: Here, we sought to comprehensively assess T cell repertoire changes during treatment in relation to: (i) treatment type [fludarabine-cyclophosphamide-rituximab (FCR) versus ibrutinib (IB) versus rituximab-idelalisib (R-ID)], and (ii) clinical response, by combining NGS immunoprofiling, flow cytometry and functional bioassays.

Results: T cell clonality significantly increased at: (i) 3 months in the FCR and R-ID treatment groups, and (ii) over deepening clinical response in the R-ID group, with a similar trend detected in the IB group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-3827DOI Listing

Clinical characteristics of four cancer patients with SARS-CoV-2 infection in Wuhan, China.

Infect Dis Poverty 2020 Jul 2;9(1):82. Epub 2020 Jul 2.

Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Donghu road 169, Wuhan, 430071, China.

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the outbreak of pneumonia in Wuhan. The virus is highly infectious. Patients with cancer might be susceptible to the viral infection because of the immunosuppressive state cause by therapies on tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40249-020-00707-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330531PMC

Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia.

J Mol Diagn 2020 Jun 29. Epub 2020 Jun 29.

Department of Pathology Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address:

Chronic lymphocytic leukemia (CLL) is a malignancy of B cells with a variable clinical course. Prognostication is important to place patients into different risk categories for guiding decisions on clinical management, to treat or not to treat. Although a number of clinical, cytogenetic and molecular parameters have been established, in the past decade, a tremendous understanding of molecular lesions has been obtained with the advent of high-throughput sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2020.06.004DOI Listing

Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.

Am J Clin Dermatol 2020 Jul 1. Epub 2020 Jul 1.

Haematology Department, Institut Universitaire du Cancer Toulouse Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocytic leukemia and other B cell malignancies. The first-generation inhibitor ibrutinib works by covalent irreversible binding to BTK, a non-receptor tyrosine kinase of the TEC (transient erythroblastopenia of childhood) family that plays a critical role in the B-cell receptor signaling pathway. It also induces an 'off-target' inhibition of a range of other kinases including (but not limited to) epidermal growth factor receptor (EGFR), SRC, and other kinases of the TEC family (interleukin-2-inducible T-cell kinase [ITK], Tec, BMX). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-020-00535-xDOI Listing

Response in patients with -mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab.

Haematologica 2020 Jul;105(7):e382-e383

Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2020.253849DOI Listing

Paraneoplastic Pemphigus: An Indication for Treatment in Chronic Lymphocytic Leukemia.

Cureus 2020 May 27;12(5):e8316. Epub 2020 May 27.

Oncology, Mount Sinai Medical Center, Brooklyn, USA.

Paraneoplastic disorders are rare multiorgan diseases associated with hematological malignancies such as chronic lymphocytic leukemia (CLL). Some of these paraneoplasms manifest as cutaneous lesions, appearing as a simple rash, ulcers or skin thickening. The pathogenesis for this process has been described as development of certain autoimmune reactions against cell wall antigens and proteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8316DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320649PMC

B-cell maturation antigen expression across hematologic cancers: a systematic literature review.

Blood Cancer J 2020 Jun 30;10(6):73. Epub 2020 Jun 30.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

B-cell maturation antigen (BCMA) plays a critical role in regulating B-cell proliferation and survival. There is evidence for BCMA expression in various hematologic malignancies, suggesting that BCMA may play an important role as a biomarker or therapeutic target in these diseases. Given advances in understanding the role of BCMA in B-cell development and the promise of BCMA as a therapeutic target, a systematic review is needed to rigorously assess the evidence for BCMA expression and identify areas of consensus and future research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0337-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327051PMC

Influence of Rurality, Race, and Ethnicity on Non-Hodgkin Lymphoma Incidence.

Clin Lymphoma Myeloma Leuk 2020 May 16. Epub 2020 May 16.

Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.

Introduction: Exposure to lymphomagens vary by geography. The extent to which these contribute to racial and ethnic disparities in non-Hodgkin lymphoma (NHL) incidence is not well understood. We sought to evaluate the association between urban-rural status and racial and ethnic disparities in the 3 major NHL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.010DOI Listing

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.

BMC Cancer 2020 Jun 30;20(1):612. Epub 2020 Jun 30.

Research and Development, Adaptive Biotechnologies Corporation, 1551 Eastlake Ave. E, Suite 200, Seattle, WA, 98102, USA.

Background: The clonoSEQ® Assay (Adaptive Biotechnologies Corporation, Seattle, USA) identifies and tracks unique disease-associated immunoglobulin (Ig) sequences by next-generation sequencing of IgH, IgK, and IgL rearrangements and IgH-BCL1/2 translocations in malignant B cells. Here, we describe studies to validate the analytical performance of the assay using patient samples and cell lines.

Methods: Sensitivity and specificity were established by defining the limit of detection (LoD), limit of quantitation (LoQ) and limit of blank (LoB) in genomic DNA (gDNA) from 66 patients with multiple myeloma (MM), acute lymphoblastic leukemia (ALL), or chronic lymphocytic leukemia (CLL), and three cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-07077-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325652PMC

Correction to: Chronic lymphocytic leukemia.

Authors:

Ann Oncol 2011 Feb 4;22(2):492. Epub 2019 Dec 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdq725DOI Listing
February 2011

Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.

Blood 2020 Jun 30. Epub 2020 Jun 30.

Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Netherlands.

Chronic lymphocytic leukemia (CLL) cells cycle between lymph node (LN) and peripheral blood (PB) and display major shifts in Bcl-2 family members between those compartments. Specifically, Bcl-XL and Mcl-1, which are not targeted by the Bcl-2 inhibitor venetoclax, are increased in the LN. Since ibrutinib forces CLL cells out of the LN, we hypothesized that ibrutinib may thereby affect expression of Bcl-XL and Mcl-1 and sensitize CLL cells to venetoclax. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019004326DOI Listing

Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia.

JCO Oncol Pract 2020 Jun 30:OP2000022. Epub 2020 Jun 30.

Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/OP.20.00022DOI Listing

Mortality among US military participants at eight aboveground nuclear weapons test series.

Int J Radiat Biol 2020 Jun 30:1-64. Epub 2020 Jun 30.

Risk Assessment Corporation, Neeses, South Carolina, USA.

: Approximately 235,000 military personnel participated at one of 230 U.S. atmospheric nuclear weapons tests from 1945 through 1962. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09553002.2020.1787543DOI Listing

Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.

Br J Haematol 2020 Jun 29. Epub 2020 Jun 29.

Oregon Health and Science University, Portland, OR, USA.

Comorbidities influence survival in patients with chronic lymphocytic leukaemia (CLL) treated with chemo-immunotherapy or ibrutinib. While idelalisib has been studied in patients with comorbidities, their impact has not been investigated. We analysed 481 patients treated with idelalisib on two randomised trials (NCT01659021 and NCT01539512). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16879DOI Listing

Classification of Digital Pathological Images of Non-Hodgkin's Lymphoma Subtypes Based on the Fusion of Transfer Learning and Principal Component Analysis.

Med Phys 2020 Jun 27. Epub 2020 Jun 27.

School of computer and control engineering, Qiqihar university, Qiqihar, 161006, China.

Purpose: Non-Hodgkin's lymphoma (NHL) is a serious malignant disease. Delayed diagnosis will cause anemia, increased intracranial pressure, organ failure, and even lead to death. The current main trend in this area is to use deep learning (DL) for disease diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mp.14357DOI Listing

ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.

Cancer Treat Rev 2020 May 16;88:102026. Epub 2020 May 16.

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Progress in cancer therapy changed the outcome of many patients and moved therapy from chemotherapy agents to targeted drugs. Targeted drugs already changed the clinical practice in treatment of leukemias, such as imatinib (BCR/ABL inhibitor) in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), ibrutinib (Bruton's tyrosine kinase inhibitor) in chronic lymphocytic leukemia (CLL), venetoclax (BCL2 inhibitor) in CLL and acute myeloid leukemia (AML) or midostaurin (FLT3 inhibitor) in AML. In this review, we focused on DNA damage response (DDR) inhibition, specifically on inhibition of ATR-CHK1 pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102026DOI Listing

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region.

Front Oncol 2020 10;10:848. Epub 2020 Jun 10.

Institute of Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Previous studies investigated the efficacy and the safety of bendamustine (B) vs. chlorambucil (Chl) associated with rituximab (R) in fludarabine-ineligible patients with treated and untreated chronic lymphocytic leukemia (CLL). We conducted a retrospective multicenter study in the Lazio region to further evaluate and compare the efficacy and the toxicity of Chl-R and B-R regimen in CLL patients over the age of 65. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00848DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298101PMC

Clinical Relevance of +936 C>T and c.233C>T Polymorphisms in Chronic Lymphocytic Leukemia.

Genes (Basel) 2020 Jun 23;11(6). Epub 2020 Jun 23.

Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.

Angiogenesis process contributes to the pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL) being the levels of VEGFA and bFGF higher in patients than in healthy controls. Our aim was to evaluate the implication of angiogenesis factors genetic variants in the predisposition to B-CLL and their association with clinical factors and survival. We performed a population-based case-control study in 224 Spanish B-CLL patients and 476 healthy randomly selected controls to evaluate susceptibility to developing B-CLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/genes11060686DOI Listing

Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.

Eur J Cancer 2020 Jun 22;135:170-172. Epub 2020 Jun 22.

Department of Hematology, Centre Léon Bérard, Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.05.016DOI Listing

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects.

Onco Targets Ther 2020 29;13:4877-4892. Epub 2020 May 29.

Department of Oncology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, People's Republic of China.

Bruton's tyrosine kinase (BTK), a pivotal component of B-cell receptor (BCR) signaling, has been recognized as an important driver of the pathogenesis of chronic lymphocytic leukemia. Ibrutinib is a highly active and selectively irreversible inhibitor of BTK, which has been approved to be effective in both frontline and recurrent therapy of CLL. Acquired resistance has become a greater problem than initially anticipated with the widespread use of ibrutinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S249586DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266824PMC

Chromosomal alterations among age-related haematopoietic clones in Japan.

Nature 2020 Jun 24. Epub 2020 Jun 24.

Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

The extent to which the biology of oncogenesis and ageing are shaped by factors that distinguish human populations is unknown. Haematopoietic clones with acquired mutations become common with advancing age and can lead to blood cancers. Here we describe shared and population-specific patterns of genomic mutations and clonal selection in haematopoietic cells on the basis of 33,250 autosomal mosaic chromosomal alterations that we detected in 179,417 Japanese participants in the BioBank Japan cohort and compared with analogous data from the UK Biobank. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-020-2426-2DOI Listing

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.

J Immunother Cancer 2020 Jun;8(1)

Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

Background: Bispecific antibodies are promising new therapeutics in B cell malignancies. Whether they lead to potent T cell activation despite described T cell dysfunction in chronic lymphocytic leukemia (CLL), and are able to effectively target high-risk or venetoclax-resistant samples, is currently unknown.

Methods: CD19 cell lines or primary (high-risk) CLL were cocultured in vitro with healthy donor (HD) or CLL-derived T cells in the presence of a CD3xCD19 dual affinity retargeting molecule (CD3xCD19 DART). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jitc-2019-000218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319711PMC

In human visualization of ibrutinib-induced CLL compartment shift.

Cancer Immunol Res 2020 Jun 24. Epub 2020 Jun 24.

Department of Medicine I, Medical University of Vienna

Bruton's tyrosine kinase inhibitor ibrutinib is effective in treating chronic lymphocytic leukemia (CLL). However, after ibrutinib treatment initiation, patients frequently experience an increase of CLL blood cell count. This phenomenon in clinical practice is thought to reflect a "compartment shift" of CLL cells from lymph nodes to the peripheral blood, but the actual shifting has not yet been demonstrated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-19-0880DOI Listing

Chronic Lymphocytic Leukemia: Real-World Data From India.

JCO Glob Oncol 2020 Jun;6:866-872

Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Purpose: Chronic lymphocytic leukemia (CLL) is uncommon in India. There are limited studies on CLL from the Indian subcontinent.

Methods: This was a prospective study (2011-2017) of consecutively diagnosed patients with CLL at a single center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/GO.20.00032DOI Listing

The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?

Expert Rev Hematol 2020 Jun 24:1-9. Epub 2020 Jun 24.

Division of Hematology, Clinical Department of Internal Diseases, Clinical Hospital Merkur , Zagreb, Croatia.

Introduction: Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries occurring typically in elderly patients. These patients often present with comorbidities limiting treatment options. During the last decade, the treatment paradigm has rapidly changed with the introduction of novel oral targeted agents and monoclonal antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2020.1775575DOI Listing

ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia.

Br J Haematol 2020 Jun 24. Epub 2020 Jun 24.

Hematology, Department of Translational and Precision Medicine, "Sapienza" University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16910DOI Listing

In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.

Br J Haematol 2020 Jun 24. Epub 2020 Jun 24.

Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Ferrara, Italy.

In a series of 349 patients with chronic lymphocytic leukaemia (CLL), we found lower levels of signalling lymphocytic activation molecule family member 1 (SLAMF1) expression in cases with highly complex karyotypes, as defined by the presence of five or more chromosomal abnormalities (CK5; P < 0·001) and with major chromosomal structural abnormalities (P < 0·001). SLAMF1 downregulation was significantly associated with advanced Binet Stage (P = 0·001), CD38 positivity (P < 0·001), high β -microglobulin levels (P < 0·001), immunoglobulin heavy chain variable region gene (IGHV) unmutated status (P < 0·001), 11q deletion (P < 0·001), tumour protein p53 (TP53) disruption (P = 0·011) and higher risk CLL International Prognostic Index categories (P < 0·001). Multivariate analysis showed that downregulated SLAMF1 levels had independent negative prognostic impact on time-to-first treatment (P < 0·001) and overall survival (P < 0·001). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16865DOI Listing

Leukemia incidence trends at the global, regional, and national level between 1990 and 2017.

Exp Hematol Oncol 2020 19;9:14. Epub 2020 Jun 19.

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450014 China.

Background: Leukemias are a group of life-threatening malignant disorders of the blood and bone marrow. The incidence of leukemia varies by pathological types and among different populations.

Methods: We retrieved the incidence data for leukemia by sex, age, location, calendar year, and type from the Global Burden of Disease online database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-020-00170-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304189PMC

Autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia.

Clin Case Rep 2020 Jun 27;8(6):1112-1113. Epub 2020 Mar 27.

Department of Hematology Oncology Baylor College of Medicine Houston TX.

Peripheral blood smear for patients with CLL and AIHA usually shows lymphoid cells with scant cytoplasm and small round nuclei with condensed chromatin, smudge cells and spherocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2816DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303863PMC

COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia.

Eur J Haematol 2020 Jun 23. Epub 2020 Jun 23.

Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.

The number of people suffering from the new coronavirus SARS-CoV-2 continues to rise. In SARS-CoV-2, superinfection with bacteria or fungi seems to be associated with increased mortality. The role of co-infections with respiratory viral pathogens has not yet been clarified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13475DOI Listing

A population-based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival.

Eur J Haematol 2020 Jun 23. Epub 2020 Jun 23.

Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Objective: Infections in chronic lymphocytic leukemia (CLL) have been thoroughly investigated in the setting of clinical trials and single center studies. However, large cohort studies on real-world data and studies on temporal trends are lacking. We performed a nationwide study on serious bacterial infections in CLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13477DOI Listing

The multiple ways Wnt signaling contributes to acute leukemia pathogenesis.

J Leukoc Biol 2020 Jun 23. Epub 2020 Jun 23.

FIOCRUZ, Center of Technological Development in Health (CDTS), Rio de Janeiro, Brazil.

WNT proteins constitute a very conserved family of secreted glycoproteins that act as short-range ligands for signaling with critical roles in hematopoiesis, embryonic development, and tissue homeostasis. These proteins transduce signals via the canonical pathway, which is β-catenin-mediated and better-characterized, or via more diverse noncanonical pathways that are β-catenin independent and comprise the planar cell polarity (PCP) pathway and the WNT/Ca pathways. Several proteins regulate Wnt signaling through a variety of sophisticated mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/JLB.2MR0420-707RDOI Listing

Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL.

Cells 2020 Jun 18;9(6). Epub 2020 Jun 18.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.

NOTCH signaling represents a promising therapeutic target in chronic lymphocytic leukemia (CLL). We compared the anti-neoplastic effects of the nuclear NOTCH2 inhibitor gliotoxin and the pan-NOTCH γ-secretase inhibitor RO4929097 in primary CLL cells with special emphasis on the individual roles of the different NOTCH receptors. Gliotoxin rapidly induced apoptosis in all CLL cases tested, whereas RO4929097 exerted a variable and delayed effect on CLL cell viability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9061484DOI Listing

Development of a ePRO-Based Palliative Care Intervention for Cancer Patients: A Participatory Design Approach.

Stud Health Technol Inform 2020 Jun;270:941-945

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thermi, Thessaloniki, Greece.

This paper describes a qualitative study conducted in the context of developing a novel ePRO (electronic Patient Reported Outcome) based palliative care intervention for cancer patients. The aim of the study was to elicit end-users' needs, judgements of the MyPal system and recommendations for improvement. A participatory design was chosen as the value of this approach has been well established in eHealth systems' design as well as the development of novel healthcare services. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/SHTI200300DOI Listing

Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis.

Leukemia 2020 Jun 21. Epub 2020 Jun 21.

Biostatistic Unit, IRCCS Regina Elena, Roma, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0924-8DOI Listing

Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling.

Biomed Pharmacother 2020 Jun 18;129:110371. Epub 2020 Jun 18.

Department of Oncology, The Third People's Hospital of Qingdao, Qingdao City, Shandong Province, 266041, China. Electronic address:

Lung cancer still remains a leading cause of cancer mortality in the world. Obatoclax mesylate (OM), a B cell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) family antagonist, is a potential antitumor drug. However, its poor aqueous solubility restricts its clinical application. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2020.110371DOI Listing

Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing.

Leukemia 2020 Jun 19. Epub 2020 Jun 19.

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Twenty years after landmark publications, there is a consensus that the somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable (IGHV) gene is an important cornerstone for accurate risk stratification and therapeutic decision-making in patients with chronic lymphocytic leukemia (CLL). The IGHV SHM status has traditionally been determined by conventional Sanger sequencing. However, NGS has heralded a new era in medical diagnostics and immunogenetic analysis is following this trend. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0923-9DOI Listing